IL6 and cancer: This study was based on UHPLC-Q-Exactive Orbitrap-MS, network pharmacology and molecular docking technology, predicting that Caulis spatholobi could act through multiple targets such as AKT1, EGFR and IL6, mediating biological processes such as protein phosphorylation and ATP binding, and regulating multiple signaling pathways such as PI3K/Akt, Proteoglycans in cancer, AGE/RAGE, and EGFR, thereby inhibiting the progression of RIF.